WallStreetZenWallStreetZen

NASDAQ: AMGN
Amgen Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Amgen earnings were $6.6B for the trailing 12 months ending Jun 30, 2025, with 110.6% growth year over year. The latest AMGN earnings report on Jun 30, 2025 announced Q2 2025 earnings of $1.4B, down 17.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AMGN reported annual earnings of $4.1B, with -39.1% growth. The next AMGN earnings date is Oct 29, 2025.

AMGN past earnings growth

How has AMGN's earnings growth performed historically?

Company
110.6%
Industry
49.61%
Market
34.06%
AMGN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
AMGN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
AMGN's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

AMGN earnings history

Current Revenue
$34.9B
Current Earnings
$6.6B
Current Profit Margin
19%
AMGN's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

AMGN Return on Equity

Current Company
97.9%
Current Industry
60%
Current Market
30.7%
AMGN's Return on Equity (97.9%)... subscribe to Premium to read more.
High Return on Equity Performance

AMGN undefined

Current Company
7.4%
Current Industry
10.6%
AMGN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when AMGN announces earnings.

AMGN undefined

Current Company
15.37%
Current Industry
18.3%
AMGN's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AMGN vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
AMGN$15.89B$6.62B-0.02%$12.32
GILD$10.97B$6.31B+5.22%$5.05
PFE$17.31B$10.75B-5.52%$1.89
SNY$18.05B$10.74B-2.50%$4.34
BMY$13.07B$5.05B-56.56%$2.49
View Top General Drug Manufacturer Stocks

AMGN earnings dates

Next earnings date
Oct 29, 2025

Amgen Earnings Reports & History FAQ

What were Amgen's earnings last quarter?

On AMGN's earnings call on Invalid Date, Amgen (NASDAQ: AMGN) reported Q2 2025 earnings per share (EPS) of $2.66, up 91.37% year over year. Total AMGN earnings for the quarter were $1.43 billion. In the same quarter last year, Amgen's earnings per share (EPS) was $1.39.

If you're new to stock investing, here's how to buy Amgen stock.

When does Amgen report earnings?

The next AMGN earnings date is Invalid Date. Add AMGN to your watchlist to be reminded of Amgen's next earnings date.

Is Amgen profitable or losing money?

As of the last Amgen earnings report, Amgen is currently profitable. Amgen's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $6.62 billion, a 111.47% increase year over year.

What was AMGN's earnings growth in the past year?

As of Amgen's earnings date in Invalid Date, Amgen's earnings has grown 110.6% year over year. This is 60.99 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 49.61%. AMGN earnings in the past year totalled $6.62 billion.

What are Amgen's earnings expectations?

The current EPS estimate for Amgen's earnings report in Invalid Date is $5.02.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.